EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Folate-Conjugated EGCG-Capped Gold Nanoparticles for Receptor-Targeted Delivery to MCF-7 Breast Cancer Cells: Green Synthesis, Characterization and Selective Cytotoxicity

Ali Jameel, Ameer Salam Hasan, Bahaulddin jafar seger

Chemical Interactions · 06.05.2024 · 3 (1) · 39-48

DOI: 10.64354/xgej2c21 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemical Interactions, online erschienen am 06.05.2024. Verfasst von Ali Jameel und 2 weiteren Autor:innen. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer remains one of the leading causes of cancer-related mortality among women worldwide, and despite the progress made in conventional chemotherapy, the lack of selectivity between malignant and normal cells continues to limit therapeutic outcomes. In the present study, a folic acid-conjugated, epigallocatechin gallate (EGCG)-capped gold nanoparticle system (FA-EGCG-AuNPs) was developed and evaluated as a targeted delivery platform against folate receptor-positive MCF-7 breast cancer cells. The nanoparticles were prepared through a one-pot green synthesis in which EGCG served simultaneously as reducing and capping agent, a short cysteamine spacer was anchored to the gold core through Au–S chemistry to display surface primary amines, and folic acid was then coupled via EDC/NHS-mediated amide bond formation. Successful formation was confirmed by a characteristic surface plasmon resonance peak around 538 nm, while transmission electron microscopy revealed mostly spherical particles in the range of 14–28 nm. FTIR, XRD and zeta potential measurements supported the conjugation of EGCG and folic acid on the gold core. Surface FR-α expression was independently verified in all cell lines by Western blot and flow cytometry to ensure that uptake differences reflected genuine receptor density. The folate-functionalized nanoparticles displayed markedly higher cellular internalization in MCF-7 cells than their non-targeted counterparts, and the MTT assay produced an IC₅₀ of 12.4 µg/mL after 48 h of treatment, which was approximately 4-fold lower than that of free EGCG. Importantly, FA-EGCG-AuNPs were considerably less toxic to the non-cancerous HEK-293 line and to the tissue-matched non-malignant mammary line MCF-10A, giving renal- and mammary-tissue selectivity indices both above 4.5. Mechanistic studies indicated mitochondrial-mediated apoptosis driven by elevated ROS, depolarization of the mitochondrial membrane, caspase-3 activation, and arrest at the G2/M phase. Taken together, and acknowledging that MCF-7 is a moderate (not high) FR-α expressor and that in-vivo confirmation is still required, the data suggest that FA-EGCG-AuNPs could serve as a promising green theranostic candidate for targeted breast cancer therapy.

Zitieren

APA

Jameel, A., Hasan, A. S., & seger, B. J. (2024). Folate-Conjugated EGCG-Capped Gold Nanoparticles for Receptor-Targeted Delivery to MCF-7 Breast Cancer Cells: Green Synthesis, Characterization and Selective Cytotoxicity. Chemical Interactions, 3(1), 39-48. https://doi.org/10.64354/xgej2c21

Vancouver

Jameel A, Hasan AS, seger BJ. Folate-Conjugated EGCG-Capped Gold Nanoparticles for Receptor-Targeted Delivery to MCF-7 Breast Cancer Cells: Green Synthesis, Characterization and Selective Cytotoxicity. Chemical Interactions. 2024;3(1):39-48. doi:10.64354/xgej2c21

BibTeX
@article{Jameel2024,
  author = {Jameel, Ali and Hasan, Ameer Salam and seger, Bahaulddin jafar},
  title = {Folate-Conjugated EGCG-Capped Gold Nanoparticles for Receptor-Targeted Delivery to MCF-7 Breast Cancer Cells: Green Synthesis, Characterization and Selective Cytotoxicity},
  journal = {Chemical Interactions},
  year = {2024},
  volume = {3},
  number = {1},
  pages = {39--48},
  doi = {10.64354/xgej2c21}
}
Kostenlos starten →